Adverse event profiles of PCSK9 inhibitors alirocumab and evolocumab: Data mining of the FDA adverse event reporting system.

Chunmei Ji, Jinmei Bai, Jiancheng Zhou,Ying Zou,Mingming Yu

British journal of clinical pharmacology（2022）

Cited 6|Views13

No score

Abstract

Data mining of the FAERs is useful for examining PCSK9 inhibitor-induced AEs. Herein, our findings were largely consistent with clinical experience and could help clinicians improve the safety of PCSK9 inhibitors in clinical practice.

Translated text

Key words

FDA adverse event reporting system,PCSK9 inhibitors,adverse event,disproportionality analyses,reporting odds ratio

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined